The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients
Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated with the c.-1639G > A polymorphism of the vitamin K-epoxide reductase (VKORC1) gene. However, its association with the acenocoumarol dose in patients under anticoagulant therapy has not been studied. T...
| Main Authors: | , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Blackwell Publishing
2012
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/21989 |
| _version_ | 1793400168652996608 |
|---|---|
| author | Montes, R. (Ramón) Ruiz-de-Gaona, E. (Estefanía) Martinez-Gonzalez, M.A. (Miguel Ángel) Alberca, I. (Ignacio) Hermida, J. (José) |
| author_facet | Montes, R. (Ramón) Ruiz-de-Gaona, E. (Estefanía) Martinez-Gonzalez, M.A. (Miguel Ángel) Alberca, I. (Ignacio) Hermida, J. (José) |
| author_sort | Montes, R. (Ramón) |
| collection | DSpace |
| description | Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated with the c.-1639G > A polymorphism of the vitamin K-epoxide reductase (VKORC1) gene. However, its association with the acenocoumarol dose in patients under anticoagulant therapy has not been studied. The c.-1639G > A genotype of VKORC1 was determined in 113 patients on stable anticoagulation requiring low (n = 42), medium (n = 42) or high (n = 21) acenocoumarol doses. To evaluate the association between acenocoumarol requirements and the c.-1639G > A variant, multivariate logistic regression models were fitted, adjusting for age, gender, and the c.430C > T and c.1075A > C variants of cytochrome P450 2C9 (CYP2C9). A total of 90.5% of the patients in the low acenocoumarol dose group carried the A allele of VKORC1:c.-1639G > A. The A allele independently increased the odds of requiring a low acenocoumarol dose [odds ratio (OR) 9.4; 95% confidence interval (CI) 1.9-46.4; P = 0.006], especially when the homozygous form was present (OR 44.2; 95% CI 5.5-354.6; P < 0.001). The A allele was less frequent in the high dose group showing an inverse association with the requirement for high doses (OR 0.04; 95% CI 0.01-0.22; P < 0.001). The A allele of the c.-1639G > A polymorphism of VKORC1 is therefore associated with a low-dose requirement for acenocoumarol in patients receiving anticoagulant therapy. |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-21989 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2012 |
| publisher | Blackwell Publishing |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-219892022-06-29T09:41:37Z The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients Montes, R. (Ramón) Ruiz-de-Gaona, E. (Estefanía) Martinez-Gonzalez, M.A. (Miguel Ángel) Alberca, I. (Ignacio) Hermida, J. (José) Vitamin K Drugs Anticoagulation Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated with the c.-1639G > A polymorphism of the vitamin K-epoxide reductase (VKORC1) gene. However, its association with the acenocoumarol dose in patients under anticoagulant therapy has not been studied. The c.-1639G > A genotype of VKORC1 was determined in 113 patients on stable anticoagulation requiring low (n = 42), medium (n = 42) or high (n = 21) acenocoumarol doses. To evaluate the association between acenocoumarol requirements and the c.-1639G > A variant, multivariate logistic regression models were fitted, adjusting for age, gender, and the c.430C > T and c.1075A > C variants of cytochrome P450 2C9 (CYP2C9). A total of 90.5% of the patients in the low acenocoumarol dose group carried the A allele of VKORC1:c.-1639G > A. The A allele independently increased the odds of requiring a low acenocoumarol dose [odds ratio (OR) 9.4; 95% confidence interval (CI) 1.9-46.4; P = 0.006], especially when the homozygous form was present (OR 44.2; 95% CI 5.5-354.6; P < 0.001). The A allele was less frequent in the high dose group showing an inverse association with the requirement for high doses (OR 0.04; 95% CI 0.01-0.22; P < 0.001). The A allele of the c.-1639G > A polymorphism of VKORC1 is therefore associated with a low-dose requirement for acenocoumarol in patients receiving anticoagulant therapy. 2012-05-11T10:52:55Z 2012-05-11T10:52:55Z 2006 info:eu-repo/semantics/article https://hdl.handle.net/10171/21989 eng http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06007.x/abstract info:eu-repo/semantics/openAccess application/pdf Blackwell Publishing |
| spellingShingle | Vitamin K Drugs Anticoagulation Montes, R. (Ramón) Ruiz-de-Gaona, E. (Estefanía) Martinez-Gonzalez, M.A. (Miguel Ángel) Alberca, I. (Ignacio) Hermida, J. (José) The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title_full | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title_fullStr | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title_full_unstemmed | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title_short | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| title_sort | c.-1639g > a polymorphism of the vkorc1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
| topic | Vitamin K Drugs Anticoagulation |
| url | https://hdl.handle.net/10171/21989 |
| work_keys_str_mv | AT montesrramon thec1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT ruizdegaonaeestefania thec1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT martinezgonzalezmamiguelangel thec1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT albercaiignacio thec1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT hermidajjose thec1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT montesrramon c1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT ruizdegaonaeestefania c1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT martinezgonzalezmamiguelangel c1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT albercaiignacio c1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients AT hermidajjose c1639gapolymorphismofthevkorc1geneisamajordeterminantoftheresponsetoacenocoumarolinanticoagulatedpatients |